Voya Investment Management LLC boosted its holdings in shares of Cytokinetics, Incorporated (NASDAQ:CYTK – Free Report) by 26.7% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 467,096 shares of the biopharmaceutical company’s stock after buying an additional 98,398 shares during the period. Voya Investment Management LLC owned approximately 0.38% of Cytokinetics worth $30,786,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
Other hedge funds also recently added to or reduced their stakes in the company. Pictet Asset Management Holding SA boosted its holdings in Cytokinetics by 18.4% in the third quarter. Pictet Asset Management Holding SA now owns 1,374,523 shares of the biopharmaceutical company’s stock worth $90,569,000 after acquiring an additional 214,060 shares in the last quarter. Fisher Asset Management LLC grew its stake in shares of Cytokinetics by 10.1% during the third quarter. Fisher Asset Management LLC now owns 818,832 shares of the biopharmaceutical company’s stock worth $53,969,000 after acquiring an additional 75,135 shares during the last quarter. ADAR1 Capital Management LLC grew its stake in shares of Cytokinetics by 17.1% during the first quarter. ADAR1 Capital Management LLC now owns 632,556 shares of the biopharmaceutical company’s stock worth $41,692,000 after acquiring an additional 92,390 shares during the last quarter. Candriam S.C.A. increased its holdings in shares of Cytokinetics by 39.3% during the third quarter. Candriam S.C.A. now owns 617,386 shares of the biopharmaceutical company’s stock valued at $40,841,000 after acquiring an additional 174,320 shares in the last quarter. Finally, Siren L.L.C. acquired a new position in shares of Cytokinetics during the first quarter valued at about $40,466,000.
Cytokinetics Stock Performance
Cytokinetics stock opened at $50.76 on Friday. The business’s 50-day simple moving average is $61.89 and its two-hundred day simple moving average is $69.46. The company has a market cap of $7.07 billion, a PE ratio of -8.40 and a beta of 0.45. Cytokinetics, Incorporated has a fifty-two week low of $50.32 and a fifty-two week high of $88.31.
Cytokinetics (NASDAQ:CYTK – Get Free Report) last announced its quarterly earnings data on Wednesday, November 4th. The biopharmaceutical company reported ($1.37) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.43) by $0.06. The firm had revenue of $47.56 million during the quarter, compared to analysts’ expectations of $41.88 million. During the same quarter in the previous year, the business earned ($2.55) earnings per share. The company’s revenue for the quarter was up 2356.5% compared to the same quarter last year. As a group, analysts predict that Cytokinetics, Incorporated will post -5.85 EPS for the current fiscal year.
Insider Buying and Selling at Cytokinetics
In other Cytokinetics news, EVP Andrew Callos sold 10,000 shares of Cytokinetics stock in a transaction that occurred on Monday, August 31st. The shares were sold at an average price of $70.24, for a total transaction of $702,400.00. Following the completion of the sale, the executive vice president directly owned 58,555 shares in the company, valued at approximately $4,112,903.20. The trade was a 14.59% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Robert Blum sold 97,926 shares of Cytokinetics stock in a transaction that occurred on Tuesday, September 15th. The shares were sold at an average price of $69.33, for a total transaction of $6,789,209.58. Following the sale, the chief executive officer owned 385,320 shares of the company’s stock, valued at approximately $26,714,235.60. The trade was a 20.26% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 201,032 shares of company stock worth $13,320,502 in the last 90 days. Corporate insiders own 2.60% of the company’s stock.
Analyst Ratings Changes
Several equities analysts recently commented on the stock. Leerink Partners decreased their price objective on shares of Cytokinetics from $103.00 to $100.00 and set an “outperform” rating for the company in a research report on Thursday, November 5th. UBS Group reissued a “buy” rating and set a $104.00 target price on shares of Cytokinetics in a research report on Wednesday, October 14th. Truist Financial upped their price target on shares of Cytokinetics from $106.00 to $112.00 and gave the company a “buy” rating in a research note on Monday, August 10th. Barclays upped their price target on shares of Cytokinetics from $95.00 to $110.00 and gave the company an “overweight” rating in a research note on Thursday, August 13th. Finally, Royal Bank Of Canada raised their price target on shares of Cytokinetics from $112.00 to $113.00 and gave the stock an “outperform” rating in a report on Thursday, October 8th. Nineteen analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, Cytokinetics currently has an average rating of “Moderate Buy” and a consensus target price of $106.50.
Read Our Latest Analysis on Cytokinetics
Cytokinetics Company Profile
Cytokinetics is a biopharmaceutical company focused on discovering and developing medicines that target the biology of muscle function. Its research centers on therapies for conditions involving impaired cardiac muscle performance. The company’s work includes aficamten, a cardiac myosin inhibitor developed for hypertrophic cardiomyopathy, and other drug candidates designed to affect muscle contraction. Cytokinetics conducts research and clinical development through programs that may involve patients and collaborators in multiple countries.
Further Reading
- Five stocks we like better than Cytokinetics
- Survey Reveals: How Much Would People Pay for Ribeye Before Giving It Up? [2026]
- If NVIDIA Tightens Its Wallet, These 3 Stocks Could Feel It
- 3 Dividend ETFs Offering Steadier Footing in a Shaky Market
- Lazard’s New ETF Targets Monthly Income With Junk Bonds
Receive News & Ratings for Cytokinetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cytokinetics and related companies with MarketBeat.com's FREE daily email newsletter.
